Search
01/10/2023
Using evidence to decision frameworks led to guidelines of better quality and more credible and transparent recommendations
Meneses-Echavez J.F., Bidonde J., Montesinos-Guevara C., Amer Y.S., Loaiza-Betancur A.F., Tellez Tinjaca L.A., Fraile Navarro D., Poklepovic Pericic T., Tokalic R., Bala M.M., Storman D., Swierz M., Zajac J., Flórez I.D., Schünemann H., Flottorp S., Alonso-Coello P.. Using evidence to decision frameworks led to guidelines of better quality and more credible and transparent recommendations. JOURNAL OF CLINICAL EPIDEMIOLOGY. 2023; 162DOI:10.1016/j.jclinepi.2023.07.013. PMID:37517506. IF:7.300(Q1/1D).
29/09/2023
Treatment and long-term outcome in primary nephrogenic diabetes insipidus
Lopez-Garcia, SC, Downie, ML, Kim, JS, Boyer, O, Walsh, SB, Nijenhuis, T, Papizh, S, Yadav, P, Reynolds, B, Decramer, S, Besouw, M, Carrascosa, MP, La Scola, C, Trepiccione, F, Ariceta, G, Hummel, A, Dossier, C, Sayer, JA, Konrad, M, Keijzer-Veen, MG, Awan, A, Basu, B, Chauveau, D, Madariaga, L, Koster-Kamphuis, L, Furlano, M, Zacchia, M, Marzuillo, P, Tse, Y, Dursun, I, Pinarbasi, AS, Tramma, D, Hoorn, EJ, Gokce, I, Nicholls, K, Eid, LA, Sartz, L, Riordan, M, Hooman, N, Printza, N, Bonny, O, Sancho, PA, Schild, R, Sinha, R, Guarino, S, Jimenez, VM, Peña, LR, Belge, H, Devuyst, O, Wlodkowski, T, Emma, F, Levtchenko, E, Knoers, NVAM, Bichet, DG, Schaefer, F, Kleta, R, European NDI Consortium, Bockenhauer, D. Treatment and long-term outcome in primary nephrogenic diabetes insipidus. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2023; 38(10)DOI:10.1093/ndt/gfaa243. PMID:33367818. IF:4.800(Q1/2D).
26/09/2023
Polygenic risk of major depressive disorder as a risk factor for venous thromboembolism.
Ward J, Le NQ, Suryakant S, Brody JA, Amouyel P, Boland A, Bown R, Cullen B, Debette S, Deleuze JF, Emmerich J, Graham N, Germain M, Anderson JJ, Pell JP, Lyall DM, Lyall LM, Smith DJ, Wiggins KL, Soria JM, Souto JC, Morange PE, Smith NL, Trégouët DA, Sabater-Lleal M, Strawbridge RJ. Polygenic risk of major depressive disorder as a risk factor for venous thromboembolism.. Blood Advances. 2023; 7(18)DOI:10.1182/bloodadvances.2023010562. PMID:37399490. IF:7.400(Q1/2D).
26/09/2023
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.
Moreno C, Solman IG, Tam CS, Grigg A, Scarfò L, Kipps TJ, Srinivasan S, Mali RS, Zhou C, Dean JP, Szafer-Glusman E, Choi M. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.. Blood Advances. 2023; 7(18)DOI:10.1182/bloodadvances.2023010236. PMID:37315225. IF:7.400(Q1/2D).